Related by context. All words. (Click for frequent words.) 67 serum phosphate 66 liver transaminases 65 aminotransferases 65 DAS# remission 64 HBeAg seroconversion 64 tipranavir r 64 REYATAZ r arm 64 Tumor shrinkage 64 serum urate 63 serum urate levels 63 CCyR 63 TEAEs 63 annualized relapse 63 APTIVUS r 63 lopinavir r arm 62 HBeAg positive patients 62 elevated ALT 62 antiretroviral naive 62 Febrile neutropenia 62 ALT elevations 62 EXJADE 62 alanine aminotransferase 62 SGPT 62 splenectomized patients 62 ALT flares 62 deep venous thromboses 62 transaminases 62 achieved CCyR 62 subtrochanteric 62 % CI #.#-#.# [007] 62 virologic breakthrough 62 prolonged QT interval 62 iPTH 62 creatinine clearance 62 lymphocytosis 61 neutropaenia 61 aminotransferase levels 61 rebleeding 61 solifenacin 61 leucopenia 61 Hepatotoxicity 61 mcg BID 61 alanine aminotransferase ALT 61 chlorambucil 61 severe exacerbations 61 HBV DNA levels 61 CIN3 61 serum magnesium 61 aspartate aminotransferase AST 61 serum ALT 61 tumor regressions 61 arterial thromboembolic events 61 Known hypersensitivity 61 serum cortisol 61 incidence ≥ 61 ALT elevation 60 PASI scores 60 hypomagnesemia 60 achieved ACR# 60 serum HBV DNA 60 EDSS scores 60 CrCl 60 creatine kinase MB 60 aspartate aminotransferase 60 DLTs 60 Crohn Disease Activity 60 mL/min/#.# m 2 60 4mg/kg 60 progression TTP 60 severe neutropenia 60 nephrotoxicity 60 CR nPR 60 oxygen desaturation 60 achieving PASI 60 cytogenetic responses 60 certolizumab 60 elevated creatinine 60 moderate renal impairment 60 intact parathyroid hormone 60 intravascular hemolysis 60 recurrent genital herpes 60 serum aminotransferase levels 60 paraprotein 60 leukopenia 60 pCR 60 reinfarction 60 β blockers 59 AST ALT 59 intracranial hemorrhage ICH 59 prolactin levels 59 p = NS 59 anemia hemoglobin 59 complete cytogenetic response 59 mcg kg REBETOL 59 tapentadol ER 59 glomerular filtration 59 mg QD 59 recurrent glioblastoma multiforme 59 postprocedure 59 serum IGF 59 CK MB 59 CR CRu 59 extrapyramidal symptoms 59 HBeAg negative patients 59 hypophosphatemia 59 leukocyte counts 59 elevated IOP 59 mg ustekinumab 59 relapsed MM 59 octreotide LAR 59 elevated transaminases 59 definite stent thrombosis 59 parkinsonian symptoms 59 nadolol 59 TURBT 59 PREZISTA ritonavir 59 8mg/kg 59 DAS# CRP 59 response CCyR 59 PREZISTA r arm 59 hours postdose 59 nondiabetic patients 59 lumbar spine BMD 59 mg kg dose 59 hematologic toxicity 59 Retreatment 59 receiving INTRON 59 NATRECOR ® 59 serum phosphate levels 59 sUA levels 59 acute gout flares 59 virologic failure 59 QT interval prolongation 59 transaminase elevations 59 severe hypoglycemic 59 recurrent ischemia 59 SCr 59 BARACLUDE ® 59 seroprotection 59 cytopenias 59 antibody titers 58 ertapenem 58 troponin T 58 HER2 expression 58 peginterferon alfa 58 heavily pretreated 58 steroid dexamethasone 58 virologic response 58 thyroid carcinoma 58 achieved sustained virological 58 #mg/m# [001] 58 tapentadol IR 58 mmHg diastolic 58 leukocytosis 58 PRADAXA #mg 58 periprocedural 58 lymphopenia 58 mild renal insufficiency 58 lactate dehydrogenase 58 generalized edema 58 clinically meaningful reductions 58 insulin detemir 58 biochemical relapse 58 IOP lowering 58 ispinesib administered 58 Viral load 58 estramustine 58 plus methotrexate 58 HBeAg 58 atazanavir ritonavir 58 desvenlafaxine succinate 58 Postoperatively 58 μg liter 58 thromboembolic events 58 neutropenic fever 58 HbA1C levels 58 HOMA IR 58 hematologic parameters 58 HbA 1c levels 58 plasma leptin 58 aminotransferase elevations greater 58 abacavir lamivudine 58 prolactin elevation 58 tipranavir ritonavir 58 NPH insulin 58 % CI #.#-#.# [008] 58 renal toxicity 58 oxycodone CR 58 T2DM 58 sUA 58 PSA nadir 58 serum creatinine levels 58 serum uric acid 58 LV dysfunction 58 plasma HCV RNA 58 recurrent venous thromboembolism 58 bortezomib refractory 58 HBV infections 58 parasitaemia 57 lowest tertile 57 neurologic progression 57 #.#mg/dL 57 aminotransferase ALT 57 NATRECOR R 57 -#.# log# copies mL 57 hepatorenal syndrome 57 serum prostate 57 ACR# response 57 complete cytogenetic 57 corticosteroid dose 57 ipsilateral stroke 57 pT3 57 Hb A1C 57 hypoglycemic events 57 platelet reactivity 57 estimated glomerular filtration 57 placebo p = 57 SLNB 57 hepatic fibrosis 57 sustained virological response 57 fluvastatin 57 #mmHg [001] 57 serum antibody 57 TMC# r 57 pooled comparator 57 binary restenosis 57 isoproterenol 57 nonvertebral fractures 57 pulmonary capillary wedge 57 undetectable viral 57 QTcF 57 virological response 57 QTc prolongation 57 HBV DNA 57 elevated serum creatinine 57 elevated LDH 57 Preoperatively 57 glycated hemoglobin levels 57 nonobese 57 creatinine ratio 57 Psoriasis Area 57 virological failure 57 intravenous bisphosphonates 57 neutropenia dehydration dyspnea 57 gout flares 57 concomitant antibiotics 57 plasma uric acid 57 prospectively stratified 57 hsCRP levels 57 mcg mL 57 serologically active patients 57 discontinuations due 57 evaluable subjects 57 lumbar spine bone 57 ritonavir boosted 57 glycated hemoglobin HbA1c 57 nicardipine 57 hemorrhagic complications 57 corrected QT interval 57 STELARA ® 57 HIV HCV coinfected 57 recurrent VTE 57 nodal metastases 57 paresthesias 57 ACR# responses 57 serum sodium levels 57 CIMZIA TM certolizumab pegol 57 â ‰ ¥ 57 serum homocysteine 57 dose cohort 57 nonfatal MI 57 ULORIC 57 adalimumab Humira 57 seroprotective 57 albumin excretion rate 57 SCIg 57 osteopenic 57 #OHD levels 57 oral antidiabetic medication 57 mcg kg 57 pericardial effusion 57 inflammatory lesions 57 antibody titer 57 severe hypoglycemia 57 pressure natriuresis 57 candidemia 57 COPD exacerbations 57 neutropenia thrombocytopenia 57 serum potassium 57 NNRTI resistance 57 clinically meaningful improvement 56 mg/m2 dose 56 hip BMD 56 6MWD 56 depressive symptomatology 56 IELT 56 lispro 56 cerebral atrophy 56 imatinib therapy 56 Scale EDSS 56 hepatitis C genotype 56 antiangiogenic therapy 56 mg BID 56 pulmonary exacerbation 56 Scale EDSS score 56 haematological toxicity 56 renal insufficiency 56 highly emetogenic 56 postoperative mortality 56 ibandronate 56 methotrexate monotherapy 56 anastomotic leak 56 postop 56 Flu Cy 56 antiretroviral naïve 56 EpCAM expression 56 median survivals 56 advanced adenoma 56 febrile neutropenia 56 ug dose 56 diastolic hypertension 56 dyspareunia 56 plasma urate 56 liver histology 56 mcg QD 56 NIH CPSI 56 oral prednisolone 56 VIIBRYD 56 MADRS score 56 serum retinol 56 achieved PASI 56 dapagliflozin plus 56 paricalcitol 56 laboratory abnormalities 56 clomipramine 56 Serum creatinine 56 pulmonary arterial 56 EFFEXOR XR 56 serum calcium levels 56 -#.# log# 56 hypoperfusion 56 postintervention 56 lamivudine refractory patients 56 glycosylated hemoglobin HbA1c 56 Cmax 56 hepatic enzymes 56 plasma pharmacokinetics 56 oxycodone IR 56 ARCOXIA 56 PREZISTA r 56 CI #.#-#.# [001] 56 NIHSS 56 PSADT 56 microvessel density 56 rimonabant #mg 56 Severity Index PASI 56 radical prostatectomy RP 56 posttreatment 56 p = .# [002] 56 % Confidence Interval 56 PaO 2 56 detemir 56 tumor shrinkage 56 mg BID dose 56 microg 56 akinesia 56 prednisone prednisolone 56 % CI #.#-#.# [006] 56 K ras mutations 56 Virologic 56 HBeAg positive 56 baseline HbA1c 56 divalproex sodium 56 nonexposed 56 events TEAEs 56 x ULN 56 undetectable viral loads 56 fractional shortening 56 flutamide 56 nocturnal hypoglycaemia 56 normal ULN 56 detectable HCV RNA 56 graft occlusion 56 preintervention 56 serum HCV RNA 56 plasma renin activity 56 Kaplan Meier estimates 56 argatroban 56 cerebral oxygenation 56 lactate dehydrogenase LDH 56 nocturnal hypoglycemia 56 -#.# ± [002] 56 pharmacokinetic interactions 56 receiving prophylactic anticoagulation 56 mucosal healing 56 dose Iluvien 56 liver metastasis 56 Index CDAI 56 tumor histology 56 imipenem 56 asthma exacerbation 56 cEVR 56 mEq L 56 tolvaptan 56 malignancy HCM 56 radiographic progression 56 endometrial hyperplasia 56 fatigue asthenia 56 A1c levels 56 fosamprenavir 56 erythema 56 Stent thrombosis 56 UPDRS scores 56 tipranavir 56 retinal thickness 56 β blocker 56 cTnI 56 Suicidal ideation 56 interquartile range 56 bezafibrate 56 periprocedural MI 56 placebo dexamethasone 55 receiving ISENTRESS 55 eosinophil count 55 Brief Psychiatric 55 serum lactate 55 serum BDNF 55 % CI #.#-#.# [003] 55 morphometric vertebral fractures 55 TNF antagonist 55 CDAI 55 mg dose 55 NovoLog ® Mix 55 specific antigen PSA 55 extrapyramidal side 55 sensory neuropathy 55 perioperatively 55 Visual Analogue Scale VAS 55 dysuria 55 serum testosterone 55 #mg/day [001] 55 Partial Response 55 serum estradiol 55 P = .# 55 viral kinetics 55 eculizumab therapy 55 tracer uptake 55 FluCAM arm 55 pg mL 55 colorectal adenoma 55 SUVmax 55 elevated bilirubin 55 haematologic 55 analgesic medications 55 pulmonary vascular 55 liver enzymes ALT 55 undetectable HBV DNA 55 pegIFN 55 Aptivus ® 55 achieved sustained virologic 55 ADCS ADL 55 postprandial glycemia 55 femoral neck fracture 55 parasitemia 55 gout flare 55 PsA 55 antiphospholipid antibodies 55 somatostatin analog 55 macroalbuminuria 55 viral suppression 55 Primary endpoints 55 concentration Cmax 55 aminotransferase 55 Insulin sensitivity 55 thromboembolic 55 min -1 55 plasma cortisol 55 polyp recurrence 55 postoperative infections 55 beta blocker therapy 55 neurodevelopmental impairment 55 androgen depletion 55 serum concentrations 55 resected pancreatic cancer 55 Y BOCS 55 QTc intervals 55 peginterferon alfa 2a 55 J. Clin 55 doxorubicin cyclophosphamide 55 HBeAg + 55 posttransplant 55 #.#/#.# mm Hg [003] 55 #mg BID [001] 55 CVD mortality 55 median PFS 55 microbleeds 55 HF hospitalization 55 LV ejection fraction 55 multivariate adjustment 55 ng dL 55 ziconotide 55 amisulpride 55 MACCE 55 affective psychosis 55 autonomic dysfunction 55 Kinoid 55 mmol l 55 pmol L 55 Breslow thickness 55 virologic suppression 55 serum leptin 55 indinavir 55 preoperative PSA 55 tryptophan depletion 55 oral allopurinol 55 extrapyramidal symptoms EPS 55 CANCIDAS 55 PegIFN RBV 55 neurodevelopmental outcome 55 alemtuzumab treated 55 transferrin saturation 55 HIV RNA 55 HBeAg negative 55 Operative mortality 55 maintaining Hb 55 pentoxifylline 55 urinary N telopeptide 55 pyrexia mucositis sepsis febrile 55 tryptase 55 Orthostatic hypotension 55 unresectable tumors 55 radiographic findings 55 + PH# 55 aripiprazole 55 CP CPPS 55 p = #.# [003] 55 transaminase levels 55 viral titer 55 postvaccination 55 pg ml 55 seroconversion 55 serum calcium 55 CRp 55 IU ml 55 adjunctive ABILIFY 55 ventricular tachyarrhythmia 55 myeloperoxidase 55 IIIa inhibitors 55 timepoints 55 blastic phase 55 #mg/day [002] 55 GnRH agonist 55 AZT zidovudine Retrovir 55 TDF FTC 55 Doxil ® 54 genital ulcers 54 FluCAM 54 urinary albumin 54 ARB telmisartan 54 VT VF 54 INVEGA ® 54 Kaplan Meier estimate 54 neutropenic patients 54 nodular partial response 54 fluticasone salmeterol 54 recurrent UTI 54 cerebrovascular events 54 locoregional disease 54 hyperacute 54 IgG antibody 54 ventricular enlargement 54 μmol L 54 Kaplan Meier analysis 54 depressive symptom 54 Neutropenia 54 systolic dysfunction 54 cGy 54 experienced virologic failure 54 tirofiban 54 HDRS 54 plasma concentrations 54 mL kg 54 S/GSK# 54 ALT normalization 54 CI -#.# 54 arterial stenosis 54 pT2 54 #q# deletion syndrome 54 pruritis 54 FOLPI 54 severe hepatic dysfunction 54 akathisia 54 thyroglobulin 54 Erythropoietic therapies may 54 comparator arm 54 asymptomatic carotid stenosis 54 LEXIVA r 54 coinfected patients 54 serum IgE 54 serum phosphorus 54 perioperative mortality 54 hypokalemia 54 3mg/kg 54 FOLFIRI alone 54 serum parathyroid hormone 54 systolic blood pressures 54 hematologic adverse 54 receiving VICTRELIS 54 μg kg 54 Kaplan Meier 54 TPV r 54 seropositivity 54 tolterodine ER 54 anagrelide 54 serum sodium 54 prostate cancer CaP 54 gadobutrol 54 ventricular dysfunction 54 inhaled budesonide 54 bolus dose 54 del 5q MDS 54 dose proportionality 54 BENICAR HCT 54 evaluable 54 placebo p 54 baseline A1C 54 neuroleptic 54 linaclotide treated 54 moderately emetogenic 54 viral titers 54 serum albumin 54 histological subtype 54 nmol L. 54 prodromal symptoms 54 ASCUS 54 hematopoietic cancers 54 #.#/#.# mmHg [001] 54 elevated troponin 54 refractory ischemia 54 antiandrogen 54 remission CR 54 nmol liter 54 Pemetrexed 54 EDSS score 54 neutrophil counts 54 pretreatment baseline 54 Postoperative 54 confidence intervals CIs 54 chlamydial infection 54 ribavirin therapy 54 log# reduction 54 ischemia driven 54 plus dexamethasone 54 neutrophil count 54 DOXIL 54 pulmonary exacerbations 54 MIRAPEX 54 stent thromboses 54 ‰ ¥ 54 interferon alfa 2b 54 interferon ribavirin 54 tertile 54 peak plasma concentrations 54 HES CEL 54 sustained virologic response 54 quetiapine 54 daunorubicin 54 Secondary endpoints include 54 cART 54 p = .# [001] 54 serum LDL cholesterol 54 FUSILEV enhances 54 non menstrual pelvic 54 SVR# 54 histologically confirmed 54 oxcarbazepine 54 sacral neuromodulation 54 neostigmine 54 oral diclofenac 54 multivariable adjustment 54 de novo AML 54 plasma creatinine 54 ß blockers 54 plus OBT 54 symptomatic VTE 54 PCWP 54 HbA 1c 54 Score TOS 54 clinically meaningful differences 54 bcr abl 54 FIRMAGON 54 MULTAQ 54 perioperative complications 54 metastatic GIST 54 q8h 54 pruritus 54 T2 lesion volume 54 Lumbar spine 54 subclinical hypothyroidism 54 conventional DMARDs 54 ziprasidone 54 TNF blocker therapy 54 calculated creatinine clearance 54 umol L 54 myelodysplastic myeloproliferative diseases 54 ximelagatran 54 adjunctive placebo 54 leukocyte count 54 Pegasys ® 54 ACTEMRA TM 54 FOLFOX4 54 COPD exacerbation 54 XIENCE V PROMUS Stent 54 posaconazole 54 X ULN 54 postoperative complication 54 advanced adenomas 54 symptom severity 54 pamidronate 54 chronicity 54 gastric pH 54 arterial thickening 54 hyperhomocysteinemia 54 Zometa hazard 54 endometrial thickness 54 budesonide pMDI 54 cabazitaxel 54 renal cysts 54 tamsulosin 54 log# copies mL 53 adriamycin 53 psychiatric comorbidities 53 creatinine levels 53 Subgroup analyzes 53 primary patency 53 seropositive patients 53 leptin deficient mice 53 RLAI 53 coagulopathy 53 severe renal impairment 53 Refractory Hodgkin Lymphoma 53 hypocalcemia 53 #ug [001] 53 invasive carcinomas 53 etomidate 53 FOSRENOL ® 53 benazepril 53 #mg dose [002] 53 seroconverted 53 coronary stenosis 53 ejection fractions 53 QT intervals 53 symptom exacerbation 53 HSCT 53 WOMAC pain 53 ZOMIG Nasal Spray 53 Secondary endpoints included 53 virologic responses 53 hemoglobin concentrations 53 KRAS mutations occur 53 adverse cytogenetics 53 TIMP 1 53 left ventricular diastolic 53 mmHg systolic 53 mcg dose 53 Expanded Disability Status 53 nelfinavir 53 hyperintensity 53 androgen suppression 53 #mm Hg 53 HGPIN 53 upper gastrointestinal bleeding 53 mitoxantrone plus 53 hemoglobin A1c levels 53 circulating EPCs 53 rizatriptan 53 esophageal carcinoma 53 blood phenylalanine Phe 53 pyrazinamide 53 cerebrovascular accident 53 CDAI score 53 SSRI citalopram 53 serum PTH 53 cTnT levels 53 C1 INH deficiency 53 generalized anxiety disorder GAD 53 urinary excretion 53 sham injections 53 Montgomery Asberg Depression 53 Torsades de Pointes 53 hepatic fat 53 peripheral edema 53 sd = 53 PANSS scores 53 HbA1c levels 53 PSA kinetics 53 nonoperative treatment 53 evaluating tivozanib 53 lamivudine monotherapy 53 statistically significant reduction 53 mg/m2/day 53 Free Survival PFS 53 nortriptyline 53 malperfusion 53 hyperphenylalaninemia HPA due 53 ribavirin RBV 53 microalbuminuria 53 OADs 53 plus MTX 53 treat NNT 53 cranial irradiation 53 primary aldosteronism 53 daily subcutaneous injections 53 femoral shaft fracture 53 noncardiac 53 serum potassium levels 53 neutropenic 53 CK # plasma concentrations 53 μg dose 53 #mmHg [002] 53 etanercept 53 MAGE A3 ASCI 53 ZOLINZA 53 titrated glipizide 53 mg p = 53 naïve HCV 53 triglyceride concentrations 53 paclitaxel eluting stents 53 ADAS cog 53 DAPT 53 adalimumab 53 baseline PASI 53 mg TID 53 BMI z 53 biologic DMARD 53 ropivacaine 53 serum phosphorous 53 KRAS mutant tumors 53 VcMP 53 alanine transaminase 53 incontinence episodes 53 LPV r 53 mg RDEA# 53 MDRD 53 QD dosing 53 Adverse events 53 psychiatric morbidity 53 NAbs 53 asthma exacerbations 53 sweat chloride 53 NHANES III 53 NNT = 53 nausea photophobia 53 caspofungin 53 Apidra ® 53 nucleoside naive 53 urinary calcium 53 clodronate 53 colorectal adenomas 53 dexamethasone Decadron 53 linezolid 53 GH deficiency 53 Plasma concentrations 53 irbesartan 53 receiving immunosuppressive therapy 53 preoperative chemotherapy 53 rheumatoid factor 53 dalteparin 53 hemorrhagic cerebrovascular events 53 serum PSA 53 postinjury 53 multivariable analysis 53 rhGH 53 mRS 53 statistical significance p 53 lymphoid blast 53 reactogenicity 53 demonstrated clinically meaningful 53 CLINICAL STUDIES 53 #μg [002] 53 intermittent dosing 53 urinary cortisol 53 paroxetine sertraline 53 ALB # 53 Kaplan Meier survival 53 detrusor 53 inhibin B 53 HIV seroconversion 53 IFN alfa 53 EBRT 53 headache nasopharyngitis 53 underwent resection 53 lymph node metastasis 53 Complication rates 53 CIMZIA TM 53 fractional anisotropy 53 #.#ng/ml 53 entecavir 53 adefovir 53 PASI score 53 atheroma volume 53 FOLFOX6 53 suboptimal adherence 53 demonstrated antitumor activity 53 evaluable patients 53 doxorubicin docetaxel 53 piperacillin tazobactam 53 racemic albuterol 53 NSTE ACS 53 fasting plasma glucose FPG 53 thrombocytopenia 53 #mg BID [003] 53 attain statistical significance 53 #mg/dl 53 QTc interval 53 MMSE scores 53 neuroleptics 53 tegaserod 53 NMIBC 53 Peg IFN 53 severe periodontitis 53 intestinal permeability 53 abdominal pain abdominal discomfort 53 nondiabetic 53 hypercapnia 53 mm Hg systolic 53 dorsomedial 53 CFQ R 53 log# 53 dose colchicine 53 darunavir ritonavir 53 atazanavir sulfate 53 aPTT 53 comorbid disorders 53 glomerular filtration rate 53 dopaminergic therapy 53 μg mL 53 cells μL 53 thrombotic events 53 nonadherent 52 Heavy menstrual bleeding 52 hyperreflexia 52 mg qd 52 nevirapine Viramune 52 GERD symptom 52 ADCS CGIC 52 enfuvirtide 52 AGILECT R 52 avosentan 52 LVEF 52 reduce serum phosphate 52 trastuzumab Herceptin ® 52 fasting glucose levels 52 confidence interval CI 52 genotypic resistance 52 postoperative atrial fibrillation 52 severe rotavirus gastroenteritis 52 serum IgG 52 Arch Intern Med 52 squamous histology 52 nanomolar 52 radiographically 52 p ≤ 52 partial remissions 52 scintigraphic 52 Rating Scale BPRS 52 baseline FEV1 52 timepoint 52 blood Phe levels 52 odds ratios ORs 52 recurrent myocardial infarction 52 haemorrhagic stroke 52 triiodothyronine 52 μg doses 52 oral antidiabetes 52 viremia 52 LEXIVA 52 p = ns 52 prolonged QT intervals 52 nadir CD4 cell 52 intracranial hypertension 52 hemoglobin A1c HbA1c 52 clinicopathological 52 statistically nonsignificant 52 aged ≥ 52 TT genotype 52 ictal 52 adenoma recurrence 52 mg eq 52 chronic renal insufficiency 52 vaginal hysterectomy 52 bosentan 52 postoperatively 52 amoxicillin clavulanate 52 Index CDAI score 52 pegylated interferon alfa 52 locoregional recurrence 52 ULTRAM ER 52 IGFBP 3